ArticlePathogens (Basel, Switzerland)2022
Changes in Group B
Article in Pathogens (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 16 citations in OpenAlex.
- Temporal trends in Group B Streptococcus colonization, serotype distribution, and antimicrobial resistance among pregnant women in the Brazilian Amazon across the COVID-19 pandemic, 2018-2023.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- Article
- Improved detection of group BMicrobiology spectrum · 2026Article
- Pregnant women's attitudes and intentions toward tuberculosis, malaria, group B streptococcus, and respiratory syncytial virus vaccines in pregnant: Findings from a cross-sectional study of pregnant women living in Brazil, Ghana, Kenya, and Pakistan.PLOS global public health · 2026Article
- Evolving antimicrobial resistance patterns in group B streptococci: A five-year study in a high-risk pregnancy referral center in northeastern Brazil.Revista da Sociedade Brasileira de Medicina Tropical · 2026Article
- Article
- Genomic Diversity, Virulome, and Resistome ofPathogens (Basel, Switzerland) · 2025Article
- Molecular epidemiology and antibiotic resistance of group BFrontiers in cellular and infection microbiology · 2025Article
- Group B streptococcus colonization in pregnancy and neonatal outcomes: a three-year monocentric retrospective study during and after the COVID-19 pandemic.Italian journal of pediatrics · 2024Article
- Increase in methicillin-resistant Staphylococcus spp. colonization among pregnant individuals during COVID-19 pandemic.Scientific reports · 2024Article
- Macrolide resistance among Streptococcus agalactiae during COVID-19 public health emergency in Brazil.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- Anovaginal Colonization by Group BAntibiotics (Basel, Switzerland) · 2024Article
- Detection ofFrontiers in cellular and infection microbiology · 2024Article
- Distribution of group B streptococci serotypes on women nasopharynx.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious DiseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 2 countries.
Funding
Abstract
Group B Streptococcus (GBS) is a leading cause of neonatal infections. The genitourinary and gastrointestinal tract of pregnant women are the main source of transmission to newborns. This work investigated the prevalence and characterized GBS from pregnant women in Rio de Janeiro, Brazil, comparing the periods before (January 2019 to March 2020; 521) and during (May 2020 to March 2021; 285) the COVID-19 pandemic. GBS was detected in 10.8% of anovaginal samples. Considering scenarios before and during the pandemic, GBS colonization rate significantly decreased (13.8% vs. 5.3%; p = 0.0001). No clinical and sociodemographic aspect was associated with GBS carriage (p > 0.05). A total of 80%, 13.8% and 4.6% GBS strains were non-susceptible to tetracycline, erythromycin and clindamycin, respectively. Serotype Ia was the most frequent (47.7%), followed by V (23.1%), II (18.4%), III (7.7%) and Ib (3.1%). An increasing trend of serotypes Ib and V, as well as of antimicrobial resistance rates, and a decreasing trend of serotypes II and III, were observed after the pandemic onset, albeit not statistically significant (p > 0.05). The reduction in GBS colonization rates and alterations in GBS serotypes and resistance profiles during the pandemic were not due to changes in the sociodemographic profile of the population. Considering that control and preventive measures related to the COVID-19 pandemic onset have impacted other infectious diseases, these results shed light on the need for the continuous surveillance of GBS among pregnant women in the post-pandemic era.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.